insights_auto
Why is LCTX down 3,50%?
Dive Deeperchevron_right
LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
0,99 $
arrow_downward
-3,50%(-0,036) 1D
0,98 $
arrow_downward
-1,40% (-0,014)bedtimeAfter hours
Closed: 9 հոկ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
1,02 $
High
1,02 $
Low
0,98 $
Mkt. cap
251,39 մլն
Avg. vol.
1,41 մլն
Volume
1,16 մլն
52-wk high
2,09 $
52-wk low
0,88 $
EPS
-0,14 $
Beta
1,60
Shares outstanding
252,91 մլն
No. of employees
75
Open
1,02 $
High
1,02 $
Low
0,98 $
Mkt. cap
251,39 մլն
Avg. vol.
1,41 մլն
Volume
1,16 մլն
52-wk high
2,09 $
52-wk low
0,88 $
EPS
-0,14 $
Beta
1,60
Shares outstanding
252,91 մլն
No. of employees
75
News stories
From web sources and news partners
MarketBeat
·
33 րոպե առաջ
First Trust Emerging Markets AlphaDEX Fund (NASDAQ:FEM) Stock Short Interest Report for September
The Motley Fool
·
42 րոպե առաջ
Prediction: This Brilliant ETF Will Crush the S&P 500 Over the Next 20 Years
CryptoRank
·
1 ժամ առաջ
Pokémon Cards Just Crushed Bitcoin, Gold and the S&P 500 With 150% Returns
Yahoo Finance
·
2 ժամ առաջ
S&P 500 Earnings Expected to Rise 31% in Q3 as AI-Related Companies Lead Growth
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc